Targets › IL12
16 programs from 13 companies in 21 trials: 19 Phase 1, 1 Phase 2, 1 Phase 3; Oncology, Infectious disease; next expected readout Dec 2026.
Open in Phaseline: the race on IL12, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Imunon | IMNN-001 (GEN-1) IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer | IL12 | Phase 3 | Epithelial Ovarian Cancer; Ovarian Cancer | Jun 2027 |
| Geneos Therapeutics | INO-9012 plasmid encoded interleukin-12 (IL-12) vaccine adjuvant | IL12 | Phase 2 | HCC | Nov 2028 |
| National Cancer Institute (NCI) | Edodekin alfa Recombinant interleukin-12 | IL12 | Phase 1 | Metastatic Malignant Solid Neoplasm; Metastatic Head and Neck Squamous Cell Carcinoma | Dec 2026 |
| Suzhou Abogen Biosciences | ABO2011 mRNA encoding human single-chain IL-12 protein | IL12 | Phase 1 | Solid Tumor, Adult | Dec 2026 |
| Kangabio AUSTRALIA | KGX101 Heterodimeric IL-12 prodrug with masked N-terminus and ADCC-impaired IgG1 Fc fusion | IL12, IL12RB1, IL12RB2 | Phase 1 | Advanced or Metastatic Solid Tumors | Jan 2027 |
| National Cancer Institute (NCI) | INO-9012 DNA plasmid encoding interleukin-12 (IL-12) | IL12 | Phase 1 | Chronic Hepatitis | Mar 2027 |
| Washington University School of Medicine | INO-9012 Plasmid encoded IL-12 | IL12 | Phase 1 | Glioblastoma | Mar 2027 |
| Strand Therapeutics | STX-001 Self-replicating RNA encoding IL-12 delivered via lipid nanoparticle (LNP) for intratumora | IL12 | Phase 1 | Advanced Solid Tumor | May 2027 |
| M.D. Anderson Cancer Center | attIL2-T cells T-cell membrane-anchored tumor-targeted IL-12 | IL12 | Phase 1 | Soft Tissue Sarcoma | Sep 2027 |
| VLP Therapeutics | VRP-encapsulated saRNA encoding IL-12 (VLPONC-01) Viral replicon particle (saRNA) expressing IL-12 | IL12 | Phase 1 | Head and Neck Cancers- Squamous Cell | Dec 2027 |
| Inovio Pharmaceuticals | INO-9012 DNA plasmid encoding human interleukin-12 (IL-12) | IL12 | Phase 1 | Glioblastoma | Dec 2027 |
| enGene | EG-70 (detalimogene voraplasmid) Viral vector-delivered IL-12 gene therapy for intravesical bladder instillation | IL12 | Phase 1 | Superficial Bladder Cancer | Apr 2028 |
| Trogenix | TGX-007 AAV-mediated dual-payload gene therapy delivering HSV-tk and IL-12 for tumor cell killing | HSV-TK, IL12 | Phase 1 | Glioblastoma (GBM) | Mar 2030 |
| Strand Therapeutics | STX-003 LNP-formulated self-replicating mRNA encoding human IL-12 with miRNA target sites for cont | IL12 | Phase 1 | Advanced Solid Tumor | Jul 2030 |
| M.D. Anderson Cancer Center | T Cell Membrane-Anchored Tumor-Targeted IL12-Modified TIL Cell Therapy (attIL12- T cell membrane-anchored tumor-targeted IL-12 expressing tumor infiltrating lymphocyte (TI | IL12 | Phase 1 | Metastatic Soft-tissue Sarcoma | Dec 2030 |
| Sonnet BioTherapeutics | SON-1010 Recombinant IL-12 fused to albumin-binding domain (FHAB) for albumin hitchhiking and tumor | IL12 | Phase 1 | Advanced Solid Tumor | – |
Advanced Solid Tumor (3) HCC (2) Epithelial Ovarian Cancer (2) Advanced or Metastatic Solid Tumors (2) Glioblastoma (2) Solid Tumor, Adult (1) Ovarian Cancer (1) Soft Tissue Sarcoma (1) Head and Neck Cancers- Squamous Cell (1) Superficial Bladder Cancer (1) Metastatic Malignant Solid Neoplasm (1) Metastatic Head and Neck Squamous Cell Carcinoma (1)
mixed (8), protein or peptide (5), other (2), small molecule (1)
M.D. Anderson Cancer Center (2) Strand Therapeutics (2) National Cancer Institute (NCI) (2) Geneos Therapeutics (1) Suzhou Abogen Biosciences (1) Imunon (1) VLP Therapeutics (1) Sonnet BioTherapeutics (1) Kangabio AUSTRALIA (1) enGene (1) Inovio Pharmaceuticals (1) Washington University School of Medicine (1) Trogenix (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.